{"title":"激素难治性前列腺癌的化疗。","authors":"Johannes Maria Wolff","doi":"10.1159/000139884","DOIUrl":null,"url":null,"abstract":"<p><p>Research in the past 3 decades has resulted in new approaches to treat patients with hormone-refractory prostate cancer. Employing the new treatment options, we are now able to prolong survival in these patients. At present, docetaxel given on a 3-week schedule is the standard of care for patients with hormone-refractory prostate cancer. Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years.</p>","PeriodicalId":55140,"journal":{"name":"Frontiers of Radiation Therapy and Oncology","volume":"41 ","pages":"103-107"},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000139884","citationCount":"2","resultStr":"{\"title\":\"Chemotherapy in hormone-refractory prostate cancer.\",\"authors\":\"Johannes Maria Wolff\",\"doi\":\"10.1159/000139884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Research in the past 3 decades has resulted in new approaches to treat patients with hormone-refractory prostate cancer. Employing the new treatment options, we are now able to prolong survival in these patients. At present, docetaxel given on a 3-week schedule is the standard of care for patients with hormone-refractory prostate cancer. Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years.</p>\",\"PeriodicalId\":55140,\"journal\":{\"name\":\"Frontiers of Radiation Therapy and Oncology\",\"volume\":\"41 \",\"pages\":\"103-107\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000139884\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers of Radiation Therapy and Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000139884\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Radiation Therapy and Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000139884","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chemotherapy in hormone-refractory prostate cancer.
Research in the past 3 decades has resulted in new approaches to treat patients with hormone-refractory prostate cancer. Employing the new treatment options, we are now able to prolong survival in these patients. At present, docetaxel given on a 3-week schedule is the standard of care for patients with hormone-refractory prostate cancer. Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
